The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1324
In Brief: A New Hib Booster
Download PDF:   US English
Med Lett Drugs Ther. 2009 Nov 2;51(1324):88
Disclosures
Objective(s)
 Select a term to see related articles  2009   A New Hib Booster   Comvax   Haemophilus influenzae type b   Hib   Hiberix   In brief   Issue 1324   November 2   page 88   Pediatrics   PedvaxHIB   vaccines   Volume 51 

In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old. Hiberix can also be given to children 12-15 months old as a scheduled booster dose.1

1. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:1008.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article